Related Experiment Video
Updated: Dec 24, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
MiR-802 Suppresses Colorectal Cancer Cell Viability, Migration and Invasion by Targeting RAN
Hailong Feng1, Lingling Liu1, Laijing Xu1
1Department of General Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province 453100, People's Republic of China.
Purpose:
Colorectal cancer is one of the most malignant tumors in the world, and the incidence is increasing every year. MicroRNAs (miRNA) are small non-coding RNAs that are involved in a variety of physiological or pathological processes. Abnormal expression of microRNA-802 (miR-802) has been demonstrated in various types of cancer. However, the expression and biological role of miR-802 in human colorectal cancer remain largely unknown.
Methods:
Here, we used quantitative real-time PCR (qRT-PCR) to measure miR-802 expression levels in colorectal cancer tissues and cell lines. Cell Counting Kit-8 (CCK-8) was used to assess the effect of miR-802 on colorectal cancer cell viability. Migration and invasion assays were performed to determine the effect of miR-802 on metastasis of colon tumor cells by transwell analysis. Luciferase activity assays were used to confirm the target of miR-802.
Results:
The results show that miR-802 is significantly downregulated in colorectal cancer tissues and cell lines. Overexpression of miR-802 profoundly inhibited viability, migration and invasion of colorectal cancer cells. In addition, we have newly discovered that the Ras-associated nucleus (RAN) is a direct target of miR-802 which could reverse the effects induced by miR-802 overexpression in colorectal cancer cells.
Conclusion:
In conclusion, our study shows that miR-802 is downregulated in colorectal cancer, and overexpression of miR-802 inhibits colorectal cancer cell viability, migration and invasion by directly targeting RAN.
Insights
MicroRNA-802 (miR-802) is downregulated in colorectal cancer, inhibiting tumor cell viability, migration, and invasion. Overexpressing miR-802 suppresses colorectal cancer progression by targeting Ras-associated nucleus (RAN).
Area of Science:
- Molecular oncology
- Cancer biology
- Gene regulation
Background:
- Colorectal cancer (CRC) is a significant global health concern with increasing incidence.
- MicroRNAs (miRNAs) are key regulators of cellular processes, with aberrant expression linked to various cancers.
- The role of microRNA-802 (miR-802) in human colorectal cancer remains largely uncharacterized.
Purpose of the Study:
- To investigate the expression levels of miR-802 in colorectal cancer.
- To elucidate the biological function of miR-802 in colorectal cancer cell viability, migration, and invasion.
- To identify the direct molecular targets of miR-802 in colorectal cancer.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) for miR-802 expression analysis.
- Cell Counting Kit-8 (CCK-8) assays to assess cell viability.
- Transwell migration and invasion assays to evaluate metastatic potential.
- Luciferase reporter assays to confirm direct target interactions.
Main Results:
- miR-802 expression was significantly downregulated in colorectal cancer tissues and cell lines.
- Overexpression of miR-802 markedly inhibited colorectal cancer cell viability, migration, and invasion.
- Ras-associated nucleus (RAN) was identified as a direct target of miR-802, mediating its tumor-suppressive effects.
Conclusions:
- miR-802 functions as a tumor suppressor in colorectal cancer.
- Downregulation of miR-802 contributes to colorectal cancer progression.
- Targeting the miR-802/RAN axis offers a potential therapeutic strategy for colorectal cancer.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...